R
heumatoid arthritis (RA), a systemic autoimmune disease affecting 1% of the US population, is characterized by symmetric joint inflammation, which, if left untreated, results in joint destruction. 1 Despite the effective immunosuppressive therapies used to treat this condition, joint destruction requiring orthopedic surgery, such as total joint arthroplasty, is often needed to maintain patient function. 2 There has been a negligible decline in the rate of total joint arthroplasty among RA patients (4.6 in 100,000 in 1991 to 4.5 in 100,000 in 2005) especially for older patients who suffered from the disease when fewer effective treatments were available (0-to 44-year age group: 3.2% decrease; 45-to 65-year group: 0.6% decrease; and >65-year age group: 0.8% decrease). 3 Thus, for many RA patients, total joint arthroplasty remains a necessary medical treatment.
Prior research suggests that persons with RA who have undergone total joint arthroplasty are at increased risk of requiring a blood transfusion. 4 Stundner and colleagues 4 found that of patients undergoing total knee arthroplasty, patients with RA are at a 50% higher risk of requiring a blood transfusion. In one of the few studies investigating the risks of blood transfusion following total joint arthroplasty in patients with RA, Ogbemudia et al. 5 reported that 21% of patients at 1 institution received a blood transfusion. In the general population, 16% to 70% of persons undergoing total joint arthroplasty require a blood transfusion. 6 Blood transfusions expose patients to increased risks including allergic reactions, viruses and infectious diseases, fever, iron overload, lung injury, hemolytic reactions, and graft-versus-host disease, and persons who have received blood transfusions are more likely to have adverse health outcomes such as increased mortality [7] [8] [9] ; thus, identifying risk factors for receipt of a blood transfusion following total joint arthroplasty in patients with RA is important.
Patients with RA have clinical and demographic factors that could affect surgical outcomes, such as the receipt of a blood transfusion, following total joint arthroplasty. 4 For example, patients with RA are typically younger and more are female when compared with patients with osteoarthritis. 4 As another example, the location of the joint replaced has been identified as a risk factor for receipt of a blood transfusion following total joint arthroplasty. 4, 10, 11 This increased requirement for blood transfusions does not, at least in the case of total knee arthroplasty, seem to be related to an increased number of bleeding episodes for RA patients. 12 Anemia is a comorbid condition that has been a focus of prior research in patients with RA undergoing total joint arthroplasty because of its association with clinical factors such as prosthetic joint infections, increased health costs, and longer lengths of hospitalization. 2, 4, 5, 13 The prevalence of anemia among RA patients ranges from 33% to 59%, and anemia has a multifactorial etiology in this population (i.e., direct inflammatory effects, bone marrow suppression secondary to medications, impairment in the synthesis of erythropoietin due to a functional iron deficiency with high iron stores but low availability). [14] [15] [16] A low preoperative hemoglobin has been identified to significantly increase the risk of requiring a blood transfusion in patients with RA (odds ratio [OR], 14.4-21.9; p < 0.001). 5 Because of the dearth of studies investigating risk factors for blood transfusions in RA patients specifically, research conducted in the general population provided guidance for our more populationtargeted approach. In the general population, anemia has been found to be a risk factor for the receipt of a blood transfusion and adverse surgical outcomes. 11, 17, 18 Patients with anemia are 3.71 times more likely to receive a transfusion compared with those without, and persons with a lower preoperative hemoglobin require a transfusion 37.8% of the time. 19, 20 Consideration of these risk factors is key because low preoperative and postoperative hemoglobin values have also been identified as risk factors for increased length of hospital stay. 18 Although few other comorbid conditions have been studied as risk factors for the receipt of a blood transfusion in patients with RA, there are some studies investigating the risk of diabetes mellitus. 5, 21 In the general population, diabetes mellitus is 1 risk factor identified as having a poor surgical outcome in patients who have received total elbow arthroplasty. 21 In contrast, for patients with RA who underwent total joint arthroplasty, diabetes mellitus types 1 (p = 0.15) and 2 (p = 0.19) were not a risk factor for receiving a blood transfusion. 5 Consistent with this finding, the same study also found that persons with higher body mass index (BMI) were less likely to require a blood transfusion (p < 0.001). 5 Other risk factors for requiring a blood transfusion following the receipt of total joint arthroplasty in the general population include ethnicity, sex, and age. 11, 17, 19, 22, 23 Hispanics and Asian persons have been identified to have an increased risk of receiving a blood transfusion and lower preoperative hemoglobin when compared with whites, respectively. 17, 19 There are conflicting results relative to the role of sex as a risk factor for requiring a blood transfusion, regardless of RA status. Ryan et al. 19 found that women were more likely than men to have blood transfusions, and Cushner and Friedman, 22 Grosflam et al., 24 and Prasad et al. 17 found that males had a higher risk than females. Cushner and Friedman 22 found that although males had a higher preoperative hemoglobin value, they had a higher rate of intraoperative blood loss than females, contributing to the higher risk of postoperative transfusion. 22 However, in a previous study of patients with RA, there was not a significant difference in the proportion of males versus females who required a blood transfusion. 5 Advanced age also increases the probability of a patient requiring a blood transfusion. In the general population, Millett et al. 20 found that 26% of those older than 75 years required blood transfusions, and Ryan et al. 19 found that persons 85 years or older were 4.02% more likely than those persons between 18 and 44 years old to require a blood transfusion. 19 Duncan et al. 23 found that the odds of requiring a blood transfusion increased 2.2% with every additional 10 years of age. Similarly, of those with RA, persons of older age were at increased risk of requiring a blood transfusion following total joint arthroplasty (p = 0.004). 5 Finally, although some general blood management strategies have been put forward, the decision to transfuse blood on a patient in the perioperative total joint arthroplasty period is not standardized and varies from provider to provider. 11, 17, 22, 24, 25 This observation suggests that geographic area of residence might play a role in the receipt of a blood transfusion following total joint arthroplasty.
MATERIALS AND METHODS

Purpose
Because of the dearth of research reporting risk factors for requiring a blood transfusion among patients with RA, we aimed to identify clinical and demographic variables associated with the receipt of a blood transfusion following total joint arthroplasty. We also describe regional practices pertaining to the administration of blood transfusions following total joint arthroplasty in patient with RA.
Study Design and Sample
This retrospective analysis was based on a data set comprising a commercially insured population of 15 million patients annually, with 1,284,681 prescribers and 3631 health care provider designations from all geographic regions in the United States. Patients' health claim information including administrative demographic data (e.g., sex, age) and physician and facility claims data (e.g., procedure codes, diagnosis codes) were extracted from January 1, 2007, to December 31, 2009 . Medical institutional review board approval was obtained for the use of this data set.
Our sample of 3270 patients was obtained by extracting all patients with 2 diagnoses of RA (International Classification of Diseases, Ninth Revision [ICD-9] codes 714.0, 714.2, 714.4) who had undergone a total joint arthroplasty during the 2-year interval. The retained Current Procedural Terminology (CPT) codes included total knee arthroplasty (27447), total hip arthroplasty (27130), and total shoulder arthroplasty (23472). Of these patients, 291 were missing at least 1 demographic (including location of residence) or clinical factor; thus, the sample size for the logistic model was 2979. Only 1 operative event was included for each patient. If a patient had more than 1 total joint arthroplasty during the period under consideration, only the first surgery was retained in this analysis.
Measures
Demographic and Clinical Variables
Demographic information extracted from the database included age, sex (male, female), education (some college, no college education), income (quintiles based on the Congress of the United States, Congressional Budget Office, Distribution of Household Income and Federal Taxes 2008-2009), 26 race (white, other race), location of joint arthroplasty (total hip arthroplasty, total knee arthroplasty, or total shoulder arthroplasty), anemia diagnosis (yes/no), and residence (based on the US Census Regions 27 ). Based on prior research and clinical plausibility, ICD-9 codes were used to extract clinical information for comorbid conditions that could potentially affect blood loss following total joint arthroplasty including obesity/morbid obesity, diabetes mellitus, systemic lupus erythematosus (SLE), human immunodeficiency virus infection (HIV)/AIDS, cancer, and gout. 17, 28 Transfusion Status
This outcome variable was determined by assessing whether the patient had received a blood transfusion within 1 week following total joint arthroplasty (CPT code 36430; transfusion, blood or blood components).
Data Analysis
Descriptive statistics, including means and SDs or frequency distributions, were used to summarize study data. Multivariate logistic regression was used to assess the demographic and clinical factors associated with transfusion status. The Hosmer-Lemeshow goodness-of-fit test evaluated overall model fit, and variance inflation factors were used to check for multicollinearity. For these data analyses, SAS version 9.4 (SAS Institute Inc, Cary, NC) was used with an α level of 0.05.
RESULTS
The predominantly female (73.6%) and white (78.9%) sample had a mean age of 58.5 years (SD, 10.8 years; Table 1 ). The geographic region with the smallest number of patients was the Northeast (8.6%), followed by the West region (14.9%). Larger subsets of patients were from the Midwest (26.7%) and South (49.8%). The majority had at least some college education (57.0%). Half of the patients were in the 2 lowest quintiles of income (<$60,000: 50.5%); the smallest percentage of subscribers was in the highest quintile (>$150,000: 2.8%). 26 As shown in Table 1 , more than half of patients had a total knee arthroplasty (65.5%), whereas only 4.3% had total shoulder arthroplasty. In the full sample, approximately a quarter of patients were obese (25.6%) and diabetic (27.4%). Relatively few patients had SLE (12%), HIV/AIDS (0.4%), cancer (2.1%), and gout (6.3%). The majority of this sample was anemic (61.6%), and approximately one-fifth received a transfusion following surgery (19.9%).
Identification of Associated Demographic and Clinical Risk Factors
Of the demographic risk factors evaluated for association with postoperative blood transfusion among patients with RA who had received total joint arthroplasty, the factors that were significant in the logistic model included sex and geographic region of residence (Table 2 ). Of the demographic factors, race, age, education, and income were not associated with transfusion status in this patient sample. Females were more likely to receive a blood transfusion when compared with males (OR, 1.48, 95% confidence interval [CI], 1.16-1.89; p = 0.001). When compared with those in the South, patients residing in the Midwest were less likely to receive a blood transfusion following total joint arthroplasty (OR, 0.56; 95% CI, 0.44-0.71; p < 0.001). Compared with the reference group of patients in the South, the rate of transfusion was not significantly different in the Northeast (p = 0.054) or the West (p = 0.14).
Of the risk factors evaluated for association with postoperative transfusion among patients with RA who had undergone a total joint arthroplasty, the clinical factors that were significant in the logistic model included the location of joint arthroplasty and anemia status ( Table 2 ). The other clinical factors (obesity, diabetes, SLE, HIV/AIDS, cancer, and gout) were not associated with transfusion status in this patient sample. Relative to total knee arthroplasty patients, those in the sample who received total hip arthroplasty were more likely to experience a transfusion (OR, 1.39; 95% CI, 1.14-1.79; p = 0.001). With total knee arthroplasty as the reference, those who had total shoulder arthroplasty were less likely to require a transfusion (OR, 0.14; 95% CI, 0.05-0.38; p < 0.001). Patients in this sample with an anemia diagnosis were more likely to have a postoperative transfusion, compared with those without this health condition (OR, 3.30; 95% CI, 2.62-4.14; p < 0.001).
DISCUSSION
This study identified female sex, geographic region of residence, location of total joint arthroplasty, and history of anemia as risk factors for the receipt of a blood transfusion following total joint arthroplasty in patients with RA. Because there are few published articles with limited consensus on risk factors for this population, this article provides important insight that could aid in directing future research to establish best practices for transfusion management in the perioperative total joint arthroplasty period for patients with RA.
We found that females with RA have an increased risk of requiring a blood transfusion following total joint arthroplasty. One study reported an increased risk of women in the general population, 19 and 1 study reported no effect from sex in RA patients 5 ; the majority of studies investigating this variable found men to be at increased risk. 17, 22, 29 Authors of prior studies suggest that increased perioperative blood loss in men 17 and lower preoperative hemoglobin in females 22 could contribute to the need for a blood transfusion. Although our sample accurately represents the predominant female prevalence of RA, 30 the conflicting findings could be attributed to the varying composition of samples (e.g., general population, RA, predominantly white and female). With this being said, it is clear that further research should be conducted to clarify these conflicting findings in the context of perioperative blood loss and hemoglobin levels.
We found that patients residing in the Midwest were significantly less likely to receive a blood transfusion following total joint arthroplasty compared with those in the South. The differences were not significant when comparing the South to the Northeast or West. Prior research suggests that the decision to transfuse blood on a patient following total joint arthroplasty varied from provider to provider, potentially resulting in geographically different treatment practice trends. 11, 17, 22 Thus, our findings are supported by prior research. This finding elucidates a larger clinical issue-provider decision-making processes in regard to blood transfusions following total joint arthroplasty. Because of the clinical and fiscal implications of these decisions, further studies should fully describe this process in efforts to establish practice guidelines.
Race, age, race, education, and income were not associated with receiving a blood transfusion in this sample. One prior study found that race is a risk factor, thus conflicting with findings in our study. 19 These results could be due to the classification of race/ethnicity used or the high prevalence of white patients in our sample. Similarly, we did not find age to be a significant risk factor for requiring a blood transfusion in this sample of RA patients; yet, there is prior research suggesting that an increased risk exists for those of advanced age in the general population. 19, 20, 23 The difference in these findings could be attributed to the younger age of RA patients when undergoing total joint arthroplasty when compared with the general population. 4 Further prospective research should be conducted, controlling for anemia to clarify these conflicting findings among RA patients.
We evaluated comorbid conditions including obesity, diabetes, SLE, HIV/AIDS, cancer, gout, and anemia along with location of total joint arthroplasty. Only location of the total joint arthroplasty and anemia status were associated with having a blood transfusion. From our review of the literature, obesity, diabetes, anemia, and the location of the joint arthroplasty were the only clinical risk factors investigated in prior research. In a prior study of patients with RA, diabetes mellitus types 1 and 2 status was not predictive of requiring a blood transfusion, and patients with a higher BMI were less likely to require a blood transfusion. 5 These findings are in support of the results of this study, which did not find that having a diagnosis of diabetes or obesity affected the risk of requiring a blood transfusion. It is plausible that persons who are severely underweight and with poor nutrition are outliers affecting these findings. Prospective studies with in-depth data on nutritional status relative to BMI and diabetes status should be conducted.
Anemia was a clinical risk factor identified to increase risks in patients with RA who underwent total joint arthroplasty. This finding is concordant with previous studies. 5 The magnitude of the effect that we identified along with the overwhelming evidence supporting this finding suggests that this risk factor should be carefully considered by providers in the preoperative period. Once this risk factor is acknowledged in the preoperative period, initiating preventative actions could improve postsurgical outcomes. Although standardized guidelines could not be identified, Liu and colleagues 24 recently published an article providing an algorithm for blood management in the perioperative period in patients undergoing total knee arthroplasty in the general population. The algorithm suggests that persons with postoperative hemoglobin of less than 7 grams/deciliter or 8 grams/deciliter with symptoms of anemia are candidates for allogenic transfusion and that patients should undergo preoperative assessment and management of anemia. 24 The final risk factor we identified was the location of the joint replaced during total joint arthroplasty. Patients who underwent a total hip arthroplasty were significantly more likely to receive a transfusion compared with those who underwent a total knee arthroplasty. It is possible that this finding reflects that knee replacements can be performed under tourniquet control in contrast to hip replacements, which cannot. We also found that those who underwent a total shoulder arthroplasty were significantly less likely to require a blood transfusion, again compared with the knee arthroplasty group. These data conflict with at least 1 published study, which found no significant difference in transfusion requirements between hip and knee arthroplasty. 6 However, the transfusion difference may be specific to RA patients because this study did not differentiate between patient populations. Interestingly, Carling et al. 6 also demonstrated a significant difference between observed blood loss for hip as compared with knee arthroplasty. Perhaps observing the blood loss intraoperatively prompts a more liberal approach to transfusion. Our results underscore the need to evaluate risk relative to location of arthroplasty prior to surgery.
This study used retrospective data from commercial insurance database; as such, our analysis was limited by data available for medications and treatments that were charged by health care providers and paid for using insurance coverage. The data set was maintained from 2007 to 2009; therefore, it may not represent the most recent changes to clinical practice. For example, minimally invasive joint replacements likely have decreased transfusion risks. With this being said, 70% to 80% of total knee replacements are performed using the traditional approach. Because this data set represents persons with commercial insurance, study findings may not be generalizable to other populations such as those without private insurance. Although the racial/ethnic composition of the sample is not representative of the US population, it is consistent with previous studies of racial variations in total joint arthroplasty. 31 There is also the potential for inaccuracies in ICD-9 and CPT codes available for extraction from the data set. With this being said, we have validated the diagnosis of RA with 2 diagnoses codes. The modest number of persons with HIV/AIDS, cancer, and SLE is an additional limitation of this study despite our robust sample size.
CONCLUSIONS
This study identifies important demographic and clinical risk factors for the receipt of a blood transfusion in patients with RA who underwent total joint arthroplasty. Because adverse health outcomes, such as increased mortality, have been found in persons receiving blood transfusions, an understanding of the risks could change the preoperative evaluation and in turn postoperative surgical outcomes. 9 This article contributes to the body of knowledge to establish best practices and standardized guidelines for the management of RA patients in the perioperative total joint arthroplasty period.
